David J R Foster

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11252569/publications.pdf

Version: 2024-02-01

42 papers	1,495 citations	394421 19 h-index	315739 38 g-index
42 all docs	42 docs citations	42 times ranked	1610 citing authors

#	Article	IF	Citations
1	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatmentâ€Refractory Depression. Clinical Pharmacology and Therapeutics, 2022, 112, 720-729.	4.7	5
2	Population pharmacokineticâ€pharmacodynamic modelling of liquid and controlledâ€release formulations of oxycodone in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 263-276.	2.5	13
3	Pharmacometrics in Australasiaâ€”Twenty Years of Population Approach Group of Australia and New Zealand. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 701-704.	2.5	3
4	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology, 2019, 84, 1073-1087.	2.3	8
5	Population pharmacokinetics of lenalidomide in patients with Bâ€cell malignancies. British Journal of Clinical Pharmacology, 2019, 85, 924-934.	2.4	8
6	Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 201-215.	1.6	9
7	Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties. Current Topics in Medicinal Chemistry, 2019, 18, 2230-2238.	2.1	2
8	Population in vitroâ€“in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 181-197.	1.8	5
9	Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. Drugs in R and D, 2017, 17, 189-198.	2.2	7
10	Food, gastrointestinal pH, and models of oral drug absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 234-248.	4.3	197
11	A modelâ€based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 2016, 81, 1046-1057.	2.4	1
12	Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. Pharmaceutical Research, 2016, 33, 1782-1794.	3.5	27
13	A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorptionâ€”Part I: Gastrointestinal pH. AAPS Journal, 2016, 18, 1309-1321.	4.4	90
14	Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2016, 81, 113-123.	2.4	19
15	An introduction to physiologicallyâ€based pharmacokinetic models. Paediatric Anaesthesia, 2016, 26, 1036-1046.	1.1	29
16	A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorptionâ€”Part II: Gastrointestinal Transit Time. AAPS Journal, 2016, 18, 1322-1333.	4.4	58
17	Modelling the PKPD of oxycodone in experimental pain â€” Impact of opioid receptor polymorphisms. European Journal of Pharmaceutical Sciences, 2016, 86, 41-49.	4.0	3
18	ADVAN-style analytical solutions for common pharmacokinetic models. Journal of Pharmacological and Toxicological Methods, 2015, 73, 42-48.	0.7	5

#	Article	IF	Citations
19	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. British Journal of Clinical Pharmacology, 2015, 79, 777-788.	2.4	4
20	Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States. Antimicrobial Agents and Chemotherapy, 2015, 59, 5681-5696.	3.2	80
21	Pharmacokineticâ€“Pharmacodynamic Modelling of the Analgesic and Antihyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 257-267.	2.5	7
22	A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 561-576.	1.8	11
23	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 2012, 5, 53.	0.7	39
24	Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 274-284.	2.5	36
25	Simple HPLC method for determination of rosiglitazone in sheep plasma and amniotic fluid and its application in a pregnant sheep model. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 360-365.	2.8	14
26	(R)â€•and (S)â€•methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology, 2010, 70, 895-902.	2.4	23
27	A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clinical Pharmacokinetics, 2010, 49, 817-827.	3.5	24
28	Pharmacokineticâ€“Pharmacodynamic Relationships of Cognitive and Psychomotor Effects of Intravenous Buprenorphine Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 94-101.	2.5	26
29	Pharmacokineticâ€Pharmacodynamic Modeling of Morphine and Oxycodone Concentrations and Analgesic Effect in a Multimodal Experimental Pain Model. Journal of Clinical Pharmacology, 2008, 48, 619-631.	2.0	54
30	Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. European Journal of Clinical Pharmacology, 2007, 63, 1153-1159.	1.9	19
31	Stereoselective Quantification of Methadone and a d6-labeled Isotopomer Using High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass-Spectrometry: Application to a Pharmacokinetic Study in a Methadone Maintained Subject. Therapeutic Drug Monitoring, 2006, 28, 559-567.	2.0	15
32	Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. British Journal of Clinical Pharmacology, 2006, 61, 326-335.	2.4	15
33	Blood-brain equilibration kinetics of levo-Î± -acetyl-methadol using a chronically instrumented sheep preparation. British Journal of Pharmacology, 2006, 147, 209-217.	5.4	3
34	Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences, 2006, 95, 1666-1676.	3.3	24
35	Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. British Journal of Clinical Pharmacology, 2005, 60, 404-413.	2.4	20
36	The Acute Disposition of (R)- and (S)-Methadone in Brain and Lung of Sheep. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 547-570.	1.8	7

#	Article	IF	Citations
37	Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 2004, 57, 742-755.	2.4	66
38	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 2004, 58, 536-541.	2.4	17
39	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 2003, 57, 287-297.	2.4	112
40	Steadyâ€state pharmacokinetics of (R)â€•and (S)â€•methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 2000, 50, 427-440.	2.4	110
41	Methadone Nâ€demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. British Journal of Clinical Pharmacology, 1999, 47, 403-412.	2.4	161
42	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 1999, 65, 685-694.	4.7	119